Joby Aviation Announces Agreement to Acquire Resonant Sciences for $500M

What Happened
On August 8, 2026 Joby Aviation, Inc. announced it entered into a Stock Purchase Agreement to acquire Strix Holdings, Inc. and, through it, 100% of the equity of the Resonant Companies (Resonant Sciences, LLC and subsidiaries). The transaction carries a Base Purchase Price of $500,000,000, subject to customary adjustments, to be paid in cash except for stock consideration to certain management sellers. The agreement and related press release were disclosed in an 8-K filed August 11, 2026.

Key Details

• Base Purchase Price: $500,000,000 (subject to adjustments for closing cash, indebtedness, transaction expenses and net working capital).
• Stock consideration: Management Members will receive stock equal to 40% of the Purchase Price payable to them; the Share Consideration is expected to be ~ $50.0 million and will be issued as Joby common stock. Number of shares = Stock Purchase Price ÷ $7.4752 (20‑day VWAP ending two business days before the agreement).
• Closing conditions: requires a pre-closing restructuring, specified regulatory and national security approvals, no Material Adverse Effect, truthful reps & warranties and other customary conditions; target outside termination date is Feb 8, 2027 (subject to certain extensions).
• Financing / equity program: on August 11, 2026 Joby entered an Equity Distribution Agreement (ATM) with Morgan Stanley, J.P. Morgan, Allen & Co. and BofA to offer up to $750,000,000 of common stock from time to time (commission up to 3%); a prospectus supplement was filed in connection with the ATM.

Why It Matters
If completed, the deal would give Joby ownership of the Resonant Companies and involve a mix of cash and equity consideration, including an expected issuance of roughly $50M of Joby shares to management sellers. The acquisition remains subject to regulatory and other closing conditions and is not guaranteed. Separately, the new ATM facility provides Joby the flexibility to raise up to $750M of equity capital over time, which could increase the company’s share count if shares are sold under that program. Investors should note the filing’s forward‑looking statements and the stated risks tied to regulatory approvals, integration and potential dilution.